Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Inhalable Drugs Market From 2025 to 2029?

In recent times, the market size for inhalable drugs has seen substantial growth. The market is set to increase from $35.06 billion in 2024 to $36.91 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. Factors such as a rising elderly population, a preference for non-invasive treatments among patients, heightened attention to respiratory health, and the growth of emerging markets have influenced the growth in the historical phase.

The market size of inhalable drugs is predicted to experience significant growth in the upcoming years, reaching “$49.17 billion by 2029, at a compound annual growth rate (CAGR) of 7.4%. The growth during the projection period can be attributed to the increase in healthcare expenditure, rising demand for biologics, the rising emphasis on personalized medications, and regulatory support for orphan drugs. Prominent trends during the forecast period include the development of advanced respiratory drugs in animal medicine, technological advancements, and enhanced reimbursement policies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12490&type=smp

What Elements Are Contributing To Growth In The Inhalable Drugs Market?

The growth of the inhalable drug market is anticipated to be fueled by the rising incidence of respiratory ailments. Such diseases primarily impact the respiratory system encompassing the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalable drugs, which deliver medication right to the lungs, play a vital role in treating many respiratory conditions. As reported by the Australian Bureau of Statistics in December 2023, 2.5% of the population (equivalent to 638,100 individuals) in Australia suffered from COPD in 2022, with comparable rates among men (2.4%) and women (2.6%). The likelihood of current daily smokers contracting COPD (8.1%) was considerably higher than ex-smokers (4.4%) and those who had not smoked ever (1.6%). Hence, the escalating occurrence of respiratory ailments is expected to stimulate growth in the inhalable drug market in future.

The inhalable drugs market covered in this report is segmented –

1) By Product: Aerosol, Dry Powder Formulation, Spray

2) By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Other Distribution Channels

3) By Application: Respiratory Diseases, Non-Respiratory Diseases

4) By End Users: Adults, Pediatric, Geriatric

Subsegments:

1) By Aerosol: Metered Dose Inhalers (MDIs), Nebulizers, Soft Mist Inhalers

2) By Dry Powder Formulation: Dry Powder Inhalers (DPIs), Blister Packs, Capsules

3) By Spray: Nasal Sprays, Oral Sprays, Subcutaneous Sprays

What Are The Leading Trends And Opportunities In The Inhalable Drugs Sector?

One prominent trend gaining traction in the inhalable drug market is product innovations. To maintain their market status, major firms involved in the inhalable drug market are adopting advancements in inhalable medicines. For example, in July 2022, DMV-Fonterra Excipients GmbH & Co. KG, a pharmaceutical firm based in Germany, broadened its dry powder inhalation (DPI) offerings by introducing Lactohale 400. This fresh grade is modifiable to address particular pharmaceutical firm requirements and is collaboratively developed with formulators to prioritize patient outcomes. A wide range of lactose-based additives was designed to offer the correct attributes for various inhaled treatments. Lactohale 400, a ground, dry lactose variant, is suitable for DPI applications that require superior flow and cohesiveness. Its anhydrous property distinguishes it from traditionally used lactose carriers and presents a different aerosolization performance compared to lactose monohydrate of the same particle size.

Who Are The Key Contributors To Growth In The Inhalable Drugs Market?

Major companies operating in the inhalable drugs market include Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Catalent Inc., Sumitomo Pharma Co. Ltd., Intertek Group plc, AptarGroup Inc., Cipla Inc., Glenmark Pharmaceuticals Inc., Piramal Pharma Ltd., Zambon S.p.A., Sunovion Pharmaceuticals Inc., Nelson Laboratories LLC, Vectura Group Limited, Abiogen Pharma, Quotient Sciences, AeroGen Pharma, Alaxia S.A.S., Pharmaxis Ltd., Avalyn Pharma Inc., TFF Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Which Region Is Projected To Lead The Inhalable Drugs Market By 2025?

North America was the largest region in the inhalable drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12490&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model